59 / 160
611
as a non invasive method for diagnosis of non alcoholic fatty liver
disease. Hepatol Res 2015; 45: 142-51
38. Musso G, Gambino R, Cassader M, Pagano G.Meta-analysis:
Natural history of non-alcoholic fatty liver disease (NAFLD) and
diagnostic accuracy of non-invasive tests for liver disease severity.
Ann Med 2011; 43(8):617–49.
39. Yoneda M, Suzuki K, Kato S, Nonalcoholic fatty liver disease:
US-based acoustic radiation force impulse elastography.
Radiology 2010; 256(2):640-7.
40. Nierhoff J, Chavez A, Hermann E, Zeuzem S, Friedrich- Ruht M.
The efficiency of acoustic radiation force impulse imaggin for the
staging of liver fibrosis: a meta – analysis. Euro Radiol 2013; 23:
3040-53.
41. Haque M, Robinson Ch, Owen D, Yoshida E, Harris A. Comparision
of acoustic radiation force impulse imaging (ARFI) to liver biopsy
histologic scores in the evaluation of chronic liver disease: A pilot
stuy. Ann Hepatol 2010; 289-93.
42. Fierbinteanu Braticevici C, Sporea I, Panaitescu E, Tribus L. Value
of acoustic radiation force impulse imaging elastography for
non invasive evaluation of patients with nonalcoholic fatty liver
disease. Ultrasound Med Biol 2013; 39:1942-50.
43. Guzman- Aroca F, Frutos-Bernal MD, Bas A et al. Detection of non
alcoholic steatohepatitis in patients with morbid obesity before
bariatric surgery: preliminary evaluation with acoustic radiation
force impulse imaging. Euro Radiol 2012; 22:2525-32.
44. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up
of patients with NAFLD and elevated liver enzymes. Hepatology
2006; 44:865–873.
45. Farrell GC, Chitturi S, Lau GK, Sollano JD. Asia-Pacific Working Party
on NAFLD. Guidelines for the assessment and management of
non-alcoholic fatty liver disease in the Asia-Pacific..J Gastroenterol
Hepatol 2007 ; 22(6):775-7.
46. Wang RT, Koretz RL, Yee HF. Is weight reduction an effective therapy
for nonalcoholic fatty liver? A systematic review. Am J Med 2003;
115: 554-9.
47. Moschen AR, Tilg H. Nutrition in pathophysiology and treatment
of nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care
2008; 11: 620-5.
48. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted
diet and exercise in obese patients with fatty liver. J Hepatol 1997;
27: 103-7.
49. Palmer M, Schaffner F. Effect of weight reduction on hepatic
abnormalities in overweight patients. Gastroenterology 1990;
99: 1408-13.
50. Vajro P, Mandato C, Franzese A, Vitamin E treatment in pediatric
obesity-related liver disease: a randomized study. J Pediatr
Gastroenterol Nutr 2004; 38: 48-55.
51. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and
physical activity in overweight patients with chronic liver disease
results in sustained improvements in alanine aminotransferase,
fasting insulin, and quality of life. Gut 2004; 53: 413-9.
52. Huang MA, Greenson JK, Chao C, et al. One year intense nutritional
counseling results in histological improvement in patients with
non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol
2005; 100: 1072-81.
53. Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty
disease. Cochrane Database Syst Rev. 2011; (6): CD003619.
54. Thomas C, Day CP, Trenell MI. Lifestyle interventions for the
treatment of non-alcoholic fatty liver disease in adults:a
systematic review. J Hepatol 2012; 56: 255-66.
55. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic
effects of dietary weight loss in morbidly obese subjects. J Hepatol
1991; 12: 224-9.
56. SullivanS, Kirk EP, Mittendorfer B, Patterson BW, Klein S:
randomized trial of exercise effect on intrahepatic triglyceride
content and lipid kinetics in nonalcoholic fatty liver disease.
Hepatology 2012; 55: 1738-45.
57. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat
for overweight subjects with nonalcoholic steatohepatitis: A
randomized, prospective trial. Hepatology 2009; 49: 80-6.
58. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on
cardiovascular outcomes in overweight and obese subjects. N Engl
J Med 2010; 363: 905-17.
59. Chavez-Tapia NC, Tellez-Avila FI, Bedogni G, Crocè LS, Masutti F,
Tiribelli C. Systematic review and meta-analysis on the adverse
events of rimonabant treatment: considerations for its potential
use in hepatology. BMC Gastroenterol. 2009; 9:75.
60. Brolin RE. Bariatric surgery and long-term control of morbid
obesity. JAMA 2002; 288: 2793-6.
61. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of
bariatric surgery on nonalcoholic fatty liver disease: systematic
review and meta-analysis. Clin Gastroenterol Hepatol2008; 6:
1396-402.
62. Mathurin P, Hollebecque A, Arnalsteen L, et al: Prospective study
of the long-term effects of bariatric surgery on liver injury in
patients without advanced disease. Gastroenterology 2009; 137:
532-540.
63. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al.
Bariatric surgery for non-alcoholic steatohepatitis in obese
patients.Cochrane Database Syst Rev. 2010; (1): CD007340.
64. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N.
Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.
65. NICE:NICE clinical guidlelines. CG87 type 2 diabetes: the
manegment of typi 2 diabetes. In NICE, ed. 2010.
66. Donadon V,Balbi M,Ghersetti M, et al: Antidiabetic therapy and
increased risk of hepatocellular carcinoma in chronic liver disease.
World J Gastroenterol 2009; 15: 2506-2511.
67. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E,
or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;
362: 1675-85.
68. Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso
G, Vargas C, Solis-Herruzo JA: A pilot trial of fenofibrate for the
treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008;
40: 200-5.
69. El-Serag HB, Johnson ML. Hachem C, Morgana RO: Statins are
associated with a reduced risk of hepatocellular carcinoma in a
large cohort of patientes with diabetes. Gastroenterology 2009;
136: 1601-1608.
[Hígado graso no alcohólico - Dra. Lorena Castro S. y col.]